In the last 30 years, the concept of chronic heart failure (CHF) 
In the last 30 years, the concept of chronic heart failure (CHF) has changed. Before the 1970s, the fundamental pathophysiology of CHF was thought to be volumeoverload, and thereby the first line of drugs for CHF included digitalis and diuretics. In the 1970s, numerous experimental and clinical studies of cardiac function brought about the change in the concept of CHF that the main pathophysiology of CHF is regarded as pump failure and an increase in the afterload. In accordance with the concept change, positive inotropic agents and vasodilators became widely used. As is well known however, the positive inotropic agents did not improve survival but rather worsened it. In 1987, CONSENSUS study
for the first time disclosed the usefulness of the ACE inhibitor, enarapril; it improves survival of severe CHF compared with placebo. Also the V-Heft trail (2) 
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Imbalance of Cardio-Stimulating and Cardio-Protective Hormones Is a Cause of Heart Failure
Clinically, How Do We Diagnose an Imbalance of Cardio-Stimulating and Cardio-Protective Hormones?
Recently, activation of RAS in CHF is like common sense among cardiologists. For the treatment of CHF, we use RAS inhibitors, such as ACE inhibitors or ARBs as the first line drugs. In this context, the clinical monitoring of RAS activation is very helpful for the physician to optimize the dose and duration of RAS inhibitors. In CHF both systemic and local (cardiac) RASs are activated, whose activating profile is somewhat different from each other. At the early stage of CHF, cardiac RAS is activated earlier than the systemic one, and the advanced stage of CHF, systemic RAS surpasses the
F i g u r e 3 . Co n c e p t o f CHF T r e a t me n t .
F i g u r e 4 . B i o c h e mi c a l ma r k e r s f o r s y s t e mi c a n d l o c a l RAS .
F i g u r e 5 . Ch a n g e o f p l a s ma B NP a n d a l d o s t e r o n e l e v e l s i n CHF t r e a t me n t . Fig. 3) (Fig. 4) 
local one. In contrast, when the CHF is treated, systemic RAS activation is decreased rapidly, but local RAS activation remains at a high level until CHF is completely improved (
AT1 Receptor as a Stretch Receptor
Recently Zou et al (7) 
